Emergent Biosolutions (EBS) 30.65 $EBS
Downgrade Alert for Emergent Biosolutions (EBS)
Comtex SmarTrend(R) - Thu Jun 23, 3:17AM CDT
Emergent Biosolutions (NYSE:EBS) was downgraded from Outperform to Market Perform at Cowen and Company today. The stock closed yesterday at $31.33 on volume of 9.6 million shares, above average daily volume of 408,000. Emergent Biosolutions share prices have moved between a 52-week high of $44.38 and a 52-week low of $27.68 and closed yesterday at 13% above that low price at $31.33 per share. Over the last five market days, the 200-day moving average (MA) has gone up 0.3% while the 50-day MA has advanced 0.3%.
EBS: 30.65 (-0.68)
Why is Emergent BioSolutions Inc. (EBS) Down 22% Today?
Afrasiab Mian - Zacks Investment Research - Wed Jun 22, 1:36PM CDT
Emergent BioSolutions Inc. (EBS) opened down 22% on Wednesday on news that the U.S. Government issued two solicitation notices that didn???t quite live up to investors??? expectations.
EBS: 30.65 (-0.68)
Watch for Emergent Biosolutions to Potentially Rebound After Falling 21.73% Yesterday
Comtex SmarTrend(R) - Wed Jun 22, 11:52AM CDT
Emergent Biosolutions (NYSE:EBS) traded in a range yesterday that spanned from a low of $29.20 to a high of $39.21. Yesterday, the shares fell 21.7%, which took the trading range below the 3-day low of $38.86 on volume of 6.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
EBS: 30.65 (-0.68)
FDA Completes Pre-Approval Inspection of Emergent BioSolutions' Large-Scale Manufacturing Facility for BioThrax
GlobeNewswire - Tue Jun 21, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has completed its Pre-Approval Inspection (PAI) of Building 55, the company's facility for large-scale manufacturing of BioThrax (Anthrax Vaccine Adsorbed). At the conclusion of the inspection, the company received a No Action Indicated decision and no Form 483 observations. Successful completion of the PAI is one of the requirements for Building 55 licensure in connection with the company's supplemental Biologics License Application (sBLA) recently accepted by the FDA. The sBLA has a Prescription Drug User Fee Act (PDUFA) target action date of August 15, 2016.
EBS: 30.65 (-0.68)
Emergent (EBS) BioThrax sBLA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 8:13AM CDT
Emergent BioSolutions (EBS) announced that the FDA has accepted to review the company's sBLA for manufacturing BioThrax in Building 55.
EBS: 30.65 (-0.68), ANIP: 56.27 (+3.48), PFE: 34.59 (+0.12), BMY: 72.64 (+0.33)
FDA Accepts Emergent BioSolutions' Supplemental Biologics License Application for Large-Scale Manufacturing of BioThrax in Building 55
GlobeNewswire - Fri Jun 17, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Emergent's supplemental Biologics License Application (sBLA) seeking approval of the manufacture of BioThrax (Anthrax Vaccine Adsorbed) in Building 55, the company's large-scale manufacturing facility. FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 15, 2016.
EBS: 30.65 (-0.68)
Emergent (EBS) BioThrax Gets Orphan Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:48AM CDT
Emergent (EBS) announced that BioThrax was granted Orphan Drug status in the U.S.
EBS: 30.65 (-0.68), ANIP: 56.27 (+3.48), PFE: 34.59 (+0.12), BMY: 72.64 (+0.33)
23.3% Return Seen to Date on SmarTrend Emergent Biosolutions Call (EBS)
Comtex SmarTrend(R) - Tue Jun 07, 12:22AM CDT
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on March 30th, 2016 at $35.86. In approximately 2 months, Emergent Biosolutions has returned 23.31% as of today's recent price of $44.22.
EBS: 30.65 (-0.68)
Uptrend Call Working As Emergent Biosolutions Stock Rises 20.3% (EBS)
Comtex SmarTrend(R) - Fri May 27, 1:22AM CDT
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on March 30th, 2016 at $35.86. In approximately 2 months, Emergent Biosolutions has returned 20.33% as of today's recent price of $43.15.
EBS: 30.65 (-0.68)
Typhoid Fever Global Clinical Trials Review 2016 - Key Players are Novartis AG, Emergent BioSolutions & Accelovance - Research and Markets
BusinessWire - Thu May 26, 3:52PM CDT
Research and Markets has announced the addition of the "Typhoid Fever Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
EBS: 30.65 (-0.68)
Corporate Directors From Campbell Soup, Cubic, Emergent BioSolutions, MassMutual, and Navient Become NACD Fellows in Q1 2016
GlobeNewswire - Tue May 24, 8:00AM CDT
The National Association of Corporate Directors (NACD) today announced 65 corporate directors who earned NACD Fellowship--The Gold Standard Director Credential--during the first quarter of 2016. These corporate directors serve on the boards of companies such as Campbell Soup Co., Cubic Corp., Delta Dental, Emergent BioSolutions Inc., KeyCorp, MassMutual Financial Group, Navient Corp., Otter Tail Corp., Patterson Cos. Inc., PRA Group Inc., Triple-S Management Corp., and on the corporate boards of other Fortune 100, nonprofit, and private companies.
EBS: 30.65 (-0.68), KEY: 11.99 (+0.42), GTS: 24.82 (+0.22), CUB: 42.87 (+0.75), OTTR: 32.52 (-0.32)
Emergent BioSolutions Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:16PM CDT
-- Q1 2016 financial performance in line with guidance
EBS: 30.65 (-0.68)
Emergent Biosolutions to Hold Annual Meeting of Stockholders Thursday May 19, 2016 at 9:00 AM Eastern; Webcast Will Be Available
GlobeNewswire - Wed May 04, 3:15PM CDT
Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 19, 2016 beginning at 9:00 AM Eastern at the Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.
EBS: 30.65 (-0.68)
The Zacks Analyst Blog Highlights: MYR Group, Coty, Kellogg, HCA Holdings and Emergent BioSolutions
Zacks Equity Research - Zacks Investment Research - Mon May 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: MYR Group, Coty, Kellogg, HCA Holdings and Emergent BioSolutions
HCA: 79.75 (+0.45), EBS: 30.65 (-0.68), COTY: 26.73 (+0.22), MYRG: 24.88 (+0.70), K: 77.83 (+0.48)
Seattle Genetics (SGEN) Posts Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 1:09PM CDT
Seattle Genetics (SGEN) reported a loss of 15 cents per share, wider than the Zacks Consensus Estimate of a loss of 11 cents.
EBS: 30.65 (-0.68), SGEN: 40.07 (+0.96), AEGR: 1.67 (+0.11)
United (UTHR) Stock Declines Despite Q1 Earnings Beat
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 10:54AM CDT
Although United Therapeutics (UTHR) delivered an earnings beat, shares were down on the revenue miss.
EBS: 30.65 (-0.68), UTHR: 105.28 (+1.92), AEGR: 1.67 (+0.11)
Agenus' (AGEN) Q1 Loss Wider than Expected, Revenue Miss
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 10:41AM CDT
Agenus (AGEN) reported first-quarter 2016 loss of 37 cents per share, wider than the Zacks Consensus Estimate of a loss of 23 cents.
AGEN: 4.20 (+0.15), EBS: 30.65 (-0.68), AEGR: 1.67 (+0.11), GSK: 42.56 (+0.80)
Acorda (ACOR) Q1 Earnings Decline Y/Y, Ampyra in Focus
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 9:50AM CDT
Investor focus will remain on the patent challenges being faced by Acorda's (ACOR) key product, Ampyra.
BIIB: 238.62 (+4.02), EBS: 30.65 (-0.68), BITI: 25.80 (-0.71), ACOR: 26.31 (+1.04)
5 Sturdy Stocks to Play Weakest Growth in 2 Years
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:56AM CDT
Stocks in defensive groups offer a good way to earn some decent returns in this slow growth environment
HCA: 79.75 (+0.45), EBS: 30.65 (-0.68), COTY: 26.73 (+0.22), MYRG: 24.88 (+0.70), K: 77.83 (+0.48)
Alkermes (ALKS) Reports Narrower-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:31AM CDT
Alkermes (ALKS) reported a loss of 32 cents per share in the first quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 43 cents.
BIIB: 238.62 (+4.02), EBS: 30.65 (-0.68), AEGR: 1.67 (+0.11), ALKS: 43.75 (+0.71)
Downgrade Alert for Emergent Biosolutions (EBS)
Comtex SmarTrend(R) - Thu Jun 23, 3:17AM CDT
Emergent Biosolutions (NYSE:EBS) was downgraded from Outperform to Market Perform at Cowen and Company today. The stock closed yesterday at $31.33 on volume of 9.6 million shares, above average daily volume of 408,000. Emergent Biosolutions share prices have moved between a 52-week high of $44.38 and a 52-week low of $27.68 and closed yesterday at 13% above that low price at $31.33 per share. Over the last five market days, the 200-day moving average (MA) has gone up 0.3% while the 50-day MA has advanced 0.3%.
EBS: 30.65 (-0.68)
Why is Emergent BioSolutions Inc. (EBS) Down 22% Today?
Afrasiab Mian - Zacks Investment Research - Wed Jun 22, 1:36PM CDT
Emergent BioSolutions Inc. (EBS) opened down 22% on Wednesday on news that the U.S. Government issued two solicitation notices that didn???t quite live up to investors??? expectations.
EBS: 30.65 (-0.68)
Watch for Emergent Biosolutions to Potentially Rebound After Falling 21.73% Yesterday
Comtex SmarTrend(R) - Wed Jun 22, 11:52AM CDT
Emergent Biosolutions (NYSE:EBS) traded in a range yesterday that spanned from a low of $29.20 to a high of $39.21. Yesterday, the shares fell 21.7%, which took the trading range below the 3-day low of $38.86 on volume of 6.0 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
EBS: 30.65 (-0.68)
FDA Completes Pre-Approval Inspection of Emergent BioSolutions' Large-Scale Manufacturing Facility for BioThrax
GlobeNewswire - Tue Jun 21, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has completed its Pre-Approval Inspection (PAI) of Building 55, the company's facility for large-scale manufacturing of BioThrax (Anthrax Vaccine Adsorbed). At the conclusion of the inspection, the company received a No Action Indicated decision and no Form 483 observations. Successful completion of the PAI is one of the requirements for Building 55 licensure in connection with the company's supplemental Biologics License Application (sBLA) recently accepted by the FDA. The sBLA has a Prescription Drug User Fee Act (PDUFA) target action date of August 15, 2016.
EBS: 30.65 (-0.68)
Emergent (EBS) BioThrax sBLA Accepted for FDA Review
Zacks Equity Research - Zacks Investment Research - Mon Jun 20, 8:13AM CDT
Emergent BioSolutions (EBS) announced that the FDA has accepted to review the company's sBLA for manufacturing BioThrax in Building 55.
EBS: 30.65 (-0.68), ANIP: 56.27 (+3.48), PFE: 34.59 (+0.12), BMY: 72.64 (+0.33)
FDA Accepts Emergent BioSolutions' Supplemental Biologics License Application for Large-Scale Manufacturing of BioThrax in Building 55
GlobeNewswire - Fri Jun 17, 6:00AM CDT
Emergent BioSolutions Inc. (NYSE:EBS) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review Emergent's supplemental Biologics License Application (sBLA) seeking approval of the manufacture of BioThrax (Anthrax Vaccine Adsorbed) in Building 55, the company's large-scale manufacturing facility. FDA has set a Prescription Drug User Fee Act (PDUFA) target action date of August 15, 2016.
EBS: 30.65 (-0.68)
Emergent (EBS) BioThrax Gets Orphan Status in the U.S.
Zacks Equity Research - Zacks Investment Research - Thu Jun 16, 8:48AM CDT
Emergent (EBS) announced that BioThrax was granted Orphan Drug status in the U.S.
EBS: 30.65 (-0.68), ANIP: 56.27 (+3.48), PFE: 34.59 (+0.12), BMY: 72.64 (+0.33)
23.3% Return Seen to Date on SmarTrend Emergent Biosolutions Call (EBS)
Comtex SmarTrend(R) - Tue Jun 07, 12:22AM CDT
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on March 30th, 2016 at $35.86. In approximately 2 months, Emergent Biosolutions has returned 23.31% as of today's recent price of $44.22.
EBS: 30.65 (-0.68)
Uptrend Call Working As Emergent Biosolutions Stock Rises 20.3% (EBS)
Comtex SmarTrend(R) - Fri May 27, 1:22AM CDT
SmarTrend identified an Uptrend for Emergent Biosolutions (NYSE:EBS) on March 30th, 2016 at $35.86. In approximately 2 months, Emergent Biosolutions has returned 20.33% as of today's recent price of $43.15.
EBS: 30.65 (-0.68)
Typhoid Fever Global Clinical Trials Review 2016 - Key Players are Novartis AG, Emergent BioSolutions & Accelovance - Research and Markets
BusinessWire - Thu May 26, 3:52PM CDT
Research and Markets has announced the addition of the "Typhoid Fever Global Clinical Trials Review, H1, 2016" clinical trials to their offering.
EBS: 30.65 (-0.68)
Corporate Directors From Campbell Soup, Cubic, Emergent BioSolutions, MassMutual, and Navient Become NACD Fellows in Q1 2016
GlobeNewswire - Tue May 24, 8:00AM CDT
The National Association of Corporate Directors (NACD) today announced 65 corporate directors who earned NACD Fellowship--The Gold Standard Director Credential--during the first quarter of 2016. These corporate directors serve on the boards of companies such as Campbell Soup Co., Cubic Corp., Delta Dental, Emergent BioSolutions Inc., KeyCorp, MassMutual Financial Group, Navient Corp., Otter Tail Corp., Patterson Cos. Inc., PRA Group Inc., Triple-S Management Corp., and on the corporate boards of other Fortune 100, nonprofit, and private companies.
EBS: 30.65 (-0.68), KEY: 11.99 (+0.42), GTS: 24.82 (+0.22), CUB: 42.87 (+0.75), OTTR: 32.52 (-0.32)
Emergent BioSolutions Reports First Quarter 2016 Financial Results
GlobeNewswire - Thu May 05, 3:16PM CDT
-- Q1 2016 financial performance in line with guidance
EBS: 30.65 (-0.68)
Emergent Biosolutions to Hold Annual Meeting of Stockholders Thursday May 19, 2016 at 9:00 AM Eastern; Webcast Will Be Available
GlobeNewswire - Wed May 04, 3:15PM CDT
Emergent BioSolutions Inc. (NYSE:EBS) has announced that it will hold its Annual Meeting of Stockholders on Thursday, May 19, 2016 beginning at 9:00 AM Eastern at the Bethesda Marriott, 5151 Pooks Hill Road, Bethesda, MD 20814.
EBS: 30.65 (-0.68)
The Zacks Analyst Blog Highlights: MYR Group, Coty, Kellogg, HCA Holdings and Emergent BioSolutions
Zacks Equity Research - Zacks Investment Research - Mon May 02, 8:30AM CDT
The Zacks Analyst Blog Highlights: MYR Group, Coty, Kellogg, HCA Holdings and Emergent BioSolutions
HCA: 79.75 (+0.45), EBS: 30.65 (-0.68), COTY: 26.73 (+0.22), MYRG: 24.88 (+0.70), K: 77.83 (+0.48)
Seattle Genetics (SGEN) Posts Wider-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 1:09PM CDT
Seattle Genetics (SGEN) reported a loss of 15 cents per share, wider than the Zacks Consensus Estimate of a loss of 11 cents.
EBS: 30.65 (-0.68), SGEN: 40.07 (+0.96), AEGR: 1.67 (+0.11)
United (UTHR) Stock Declines Despite Q1 Earnings Beat
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 10:54AM CDT
Although United Therapeutics (UTHR) delivered an earnings beat, shares were down on the revenue miss.
EBS: 30.65 (-0.68), UTHR: 105.28 (+1.92), AEGR: 1.67 (+0.11)
Agenus' (AGEN) Q1 Loss Wider than Expected, Revenue Miss
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 10:41AM CDT
Agenus (AGEN) reported first-quarter 2016 loss of 37 cents per share, wider than the Zacks Consensus Estimate of a loss of 23 cents.
AGEN: 4.20 (+0.15), EBS: 30.65 (-0.68), AEGR: 1.67 (+0.11), GSK: 42.56 (+0.80)
Acorda (ACOR) Q1 Earnings Decline Y/Y, Ampyra in Focus
Arpita Dutt - Zacks Investment Research - Fri Apr 29, 9:50AM CDT
Investor focus will remain on the patent challenges being faced by Acorda's (ACOR) key product, Ampyra.
BIIB: 238.62 (+4.02), EBS: 30.65 (-0.68), BITI: 25.80 (-0.71), ACOR: 26.31 (+1.04)
5 Sturdy Stocks to Play Weakest Growth in 2 Years
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:56AM CDT
Stocks in defensive groups offer a good way to earn some decent returns in this slow growth environment
HCA: 79.75 (+0.45), EBS: 30.65 (-0.68), COTY: 26.73 (+0.22), MYRG: 24.88 (+0.70), K: 77.83 (+0.48)
Alkermes (ALKS) Reports Narrower-than-Expected Q1 Loss
Zacks Equity Research - Zacks Investment Research - Fri Apr 29, 8:31AM CDT
Alkermes (ALKS) reported a loss of 32 cents per share in the first quarter of 2016, narrower than the Zacks Consensus Estimate of a loss of 43 cents.
BIIB: 238.62 (+4.02), EBS: 30.65 (-0.68), AEGR: 1.67 (+0.11), ALKS: 43.75 (+0.71)
